How do pharma, biotech and medtech manufacturers optimize their supply chain management for stable supply while keeping working capital under control?

Supply chain management in a regulated environment rarely fails because of a single bad forecast, but because of the sequence of planning. As long as demand planning, production and procurement operate on separate cadences, each function corrects the assumptions of the others, and every correction ends up either as overstock or as a supply gap. The S&OP process addresses exactly this point: it brings supply and demand into a shared monthly cadence in which conflicts become visible before they reach production. Only on this basis does a better forecasting methodology pay off, because the more accurate figure lands in a plan that every function follows.

The second logic is that of the bottleneck: in the supply chain, not every material is equally critical. Long lead times of critical suppliers and the limited shelf life of GMP materials determine where safety stock protects supply and where it merely ties up capital and generates write-offs. A risk-based inventory strategy therefore differentiates by criticality and shelf life rather than by a blanket ratio, and supplier management concentrates metrics and reviews on the suppliers whose failure would hit production first. Above all of this lies the required traceability of the distribution chain under Good Distribution Practice, as well as UDI traceability for medical devices and IVDs. Both belong built into the operational flow, not documented after the fact.